It’s getting harder and harder to make a splash with personalized CAR-Ts for leukemia and lymphoma, but Celgene is giving it a go today at ASH.
Their CAR-T team at Juno — now a subsidiary of Celgene’s — offered up a stellar round of objective responses rates for JCAR017 in their Phase I/II study for a small group of high-risk patients suffering from drug resistant chronic lymphocytic leukemia and small lymphocytic lymphoma.
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 41,700+ biopharma pros who read Endpoints News by email every day.Free Subscription